Evidence map›Paper›PMID 38905595›Full record

ArticleBlood advances2024

Neurobeachin regulates hematopoietic progenitor differentiation and survival by modulating Notch activity.

Miguel Ganuza, Antonio Morales-Hernández, Alanna Van Huizen, Ashley Chabot, Trent Hall, Claire Caprio, David Finkelstein, Manfred W Kilimann, Shannon McKinney-Freeman

Abstract read
In one paragraph

Article in Blood advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Miguel GanuzaCentre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.ORCID 0000-0002-1070-7961
Antonio Morales-HernándezDepartment of Periodontics and Oral Medicine, University of Michigan School of Dentistry, Ann Arbor, MI.
Alanna Van HuizenDepartment of Hematology, St. Jude Children's Research Hospital, Memphis, TN.
Ashley ChabotDepartment of Hematology, St. Jude Children's Research Hospital, Memphis, TN.
Trent HallDepartment of Hematology, St. Jude Children's Research Hospital, Memphis, TN.
Claire CaprioDepartment of Hematology, St. Jude Children's Research Hospital, Memphis, TN.
David FinkelsteinDepartment of Computational Biology, St. Jude Children's Research Hospital, Memphis, TN.
Manfred W KilimannDepartment of Molecular Neurobiology, Max-Planck Institute for Multidisciplinary Sciences, Göttingen, Germany.
Shannon McKinney-FreemanDepartment of Hematology, St. Jude Children's Research Hospital, Memphis, TN.ORCID 0000-0001-8061-2557

Funding

Viral Vector Technology (VVTSR)P30CA021765 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI Shondra Michelle Miller · 1985 to 2026
$166.9M
Childhood Hematological Malignancies Training ProgramT32CA236748 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI Charles G Mullighan · 2019 to 2026
$2.0M
Defining Nfix's role as a novel key regulator of hematopoietic stem cellsR01DK104028 · NIDDK · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI MCKINNEY-FREEMAN, SHANNON L · 2016 to 2020
$2.0M
Characterization of embryonic stem cell-derived hematopoietic stem cellsK01DK080846 · NIDDK · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI MCKINNEY-FREEMAN, SHANNON L · 2008 to 2012
$771k
Gprasp2 expression identifies a deeply quiescent hematopoietic stem cells subset with superior stemness and self-renewalF32DK135334 · NIDDK · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI VAN HUIZEN, ALANNA V · 2023 to 2023
$70k
NCI NIH HHS P30 CA021765NCI NIH HHS T32 CA236748NIDDK NIH HHS F32 DK135334NIDDK NIH HHS K01 DK080846NIDDK NIH HHS R01 DK104028
6 · The paper itself

Abstract

abstractHematopoietic stem cells (HSCs) can generate all blood cells. This ability is exploited in HSC transplantation (HSCT) to treat hematologic disease. A clear understanding of the molecular mechanisms that regulate HSCT is necessary to continue improving transplant protocols. We identified the Beige and Chediak-Higashi domain-containing protein (BDCP), Neurobeachin (NBEA), as a putative regulator of HSCT. Here, we demonstrated that NBEA and related BDCPs, including LPS Responsive Beige-Like Anchor Protein (LRBA), Neurobeachin Like 1 (NBEAL1) and Lysosomal Trafficking Regulator (LYST), are required during HSCT to efficiently reconstitute the hematopoietic system of lethally irradiated mice. Nbea knockdown in mouse HSCs induced apoptosis and a differentiation block after transplantation. Nbea deficiency in hematopoietic progenitor cells perturbed the expression of genes implicated in vesicle trafficking and led to changes in NOTCH receptor localization. This resulted in perturbation of the NOTCH transcriptional program, which is required for efficient HSC engraftment. In summary, our findings reveal a novel role for NBEA in the control of NOTCH receptor turnover in hematopoietic cells and supports a model in which BDCP-regulated vesicle trafficking is required for efficient HSCT.

Indexed as

Cell DifferentiationHematopoietic Stem CellsHematopoietic Stem Cell TransplantationReceptors, NotchAnimalsApoptosisCell SurvivalMiceNerve Tissue ProteinsNerve Tissue ProteinsReceptors, Notch

Identifiers

PMID38905595
PMCPMC11345395

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.